HANK & LIN'S GROUP

Publication

1.Zha, Zhihao, Seok Rye Choi, Linlin Li, Ruiyue Zhao, Karl Ploessl, Xinyue Yao, David Alexoff, Lin Zhu, and Hank F. Kung. "New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)." Journal of Medicinal Chemistry (2022).

2.Zhao, Ruiyue, Karl Ploessl, Zhihao Zha, Seokrye Choi, David Alexoff, Lin Zhu, and Hank F. Kung. "Synthesis and Evaluation of ⁶⁸Ga-and ¹⁷⁷Lu-Labeled (R)-vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives." Molecular Pharmaceutics 17, no. 12 (2020): 4589-4602.

3.Yao, Xinyue, Zhihao Zha, Karl Ploessl, Seok Rye Choi, Ruiyue Zhao, David Alexoff, Lin Zhu, and Hank F. Kung. "Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer." Bioorganic & Medicinal Chemistry 28, no. 5 (2020): 115319.

4.Kung, H., Choi, S. R., Zha, Z., Ploessl, K., & Alexoff, D. (2019, May). [Ga-68]/[Lu-177] P17-087: A potential theranostic agent targeting PSMA expressing tumor. In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (Vol. 62, pp. S99-S100). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.